Sepsis and scientific revolutions

Critical Care Medicine

Volumn 41, Issue 12, 2013, Pages 2770-2772

  Artenstein, Andrew W ^a   Higgins, Thomas L ^a   Opal, Steven M ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Paradigm shift; Sepsis; Therapeutic revolution

Indexed keywords

ALBUMIN; ANTIINFECTIVE AGENT; ANTITHROMBIN; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BETA2 INTEGRIN ANTIBODY; CHIMERIC TUMOR NECROSIS FACTOR MONOCLONAL ANTIBODY; COMPLEMENT COMPONENT 1 ESTERASE INHIBITOR; DROTRECOGIN; ERITORAN; ESCHERICHIA COLI J5 ANTISERUM; HEPARIN; HUMANIZED TUMOR NECROSIS FACTOR MONOCLONAL ANTIBODY; IBUPROFEN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LIPID A E5 MONOCLONAL ANTIBODY; LIPID A HA1A MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD14; NEMATODE ANTICOAGULANT PROTEIN C2; NITRIC OXIDE SYNTHASE INHIBITOR; PAF ACETYL HYDROLASE; PMX B COLUMN; PMX B CONJUGANT; RESATORVID; STEROID; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR BINDING FRAGMENT OF IMMUNOGLOBULIN; TUMOR NECROSIS FACTOR MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BACTERIAL INFECTION; CRITICAL ILLNESS; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ESCHERICHIA COLI; GLYCEMIC CONTROL; HEMOPERFUSION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SEPSIS;

EID: 84889239723     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31829eb98f     Document Type: Article

References (14)

1. Kuhn TS: The Structure of Scientific Revolutions. Chicago, The University of Chicago Press, 1962
2. Buchman TG: Nonlinear dynamics, complex systems, and the pathobiology of critical illness. Curr Opin Crit Care 2004; 10:378-382 (Pubitemid 39313508)
3. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24:1125-1128
4. Janeway CA Jr: The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 1992; 13:11-16
5. Hotchkiss RS, Opal S: Immunotherapy for sepsis-A new approach against an ancient foe. N Engl J Med 2010; 363:87-89
6. Matzinger P: The danger model: A renewed sense of self. Science 2002; 296:301-305 (Pubitemid 34303674)
7. Cohen J, Opal S, Calandra T: Sepsis studies need new direction. Lancet Infect Dis 2012; 12:503-505
8. Foster SL, Hargreaves DC, Medzhitov R: Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007; 447:972-978 (Pubitemid 46975746)
9. Cavaillon JM, Adib-Conquy M: Bench-to-bedside review: Endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care 2006; 10:233
10. Venet F, Filipe-Santos O, Lepape A, et al. Decreased T-cell repertoire diversity in sepsis: A preliminary study. Crit Care Med 2013; 41:111-119
11. Salomao R, Brunialti MK, Rapozo MM, et al. Bacterial sensing, cell signaling, and modulation of the immune response during sepsis. Shock 2012; 38:227-242
12. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150 (Pubitemid 36056721)
13. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637
14. Levy MM, Dellinger RP, Townsend SR, et al. Surviving Sepsis Campaign: The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med 2010; 38:367-374